De Facto Medica, Bell Pottinger Groups' medical education company, has been selected by Lyon based Merck Santé to provide medical education, branding, advertising, marketing and PR support globally for its type 2 diabetes product, Glucovance®. De Facto Medica won the account with Merck Santé after a three way pitch with Adis International and Shire Health International. Glucovance® is a fixed combination tablet consisting of glibenclamide and metformin HCI, two of the most widely prescribed oral antihyperglycemic drugs worldwide.
"Merck Santé is pleased to have chosen De Facto Medica for the provision of medical education, PR and advertising globally for Glucovance. We were impressed with De Facto Medica's knowledge and strategic understanding of our business and the diabetes market ," said the Glucovance Marketing Manager.
"We are absolutely delighted to win this account and become a partner to Merck Santé. We are excited about developing the global programme for Glucovance® and our aim is to ensure the product achieves tremendous success," says Marcel Kay, Director, De Facto Medica.
- ends -
For further information , please contact:
Marcel Kay at De Facto Medica either via email: m.kay@defacto.com or call +44 (0) 20 7861 3027.
About De Facto Medica De Facto Medica is a subsidiary of De Facto Communications and offers tailored Medical Education services. As a fresh and vibrant communications agency, we specialise in dedicated medical education services at all stages of a pharmaceutical product's development from Phase I to IV.
